文献速递肿瘤 PET/CT核素与放射性配体治疗

44Sc-PSMA-617用于与177Lu-PSMA-617配对的放射诊疗:与68Ga-PSMA-11和68Ga-PSMA-617的临床前比较研究

44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617.
PubMed 文献 · EJNMMI Res · 2017-01-19

本研究将回旋加速器生产的44Sc标记PSMA-617,在体外和PC-3 PIP/flu荷瘤小鼠中与177Lu-PSMA-617、68Ga-PSMA-617及68Ga-PSMA-11比较。44Sc-PSMA-617的体外特性和体内动力学更接近177Lu-PSMA-617,且因44Sc半衰期约为68Ga的四倍,可实现集中生产并配送至卫星PET中心。

要点

  • 44Sc-PSMA-617放化纯度>97%,比活度最高10 MBq/nmol。
  • 44Sc-PSMA-617体外特性与177Lu-和68Ga标记的PSMA-617相似。
  • 44Sc-PSMA-617体内分布最接近177Lu-PSMA-617,肿瘤摄取高、肾脏排泄快。

核心结论

  • 44Sc-PSMA-617的体外特性和体内动力学更接近177Lu-PSMA-617,而非68Ga-PSMA-617和68Ga-PSMA-11。
  • 由于44Sc半衰期几乎为68Ga的四倍,44Sc-PSMA-617的集中生产并运输至卫星PET中心是可行的。
  • 这些特征使44Sc-PSMA-617对临床应用特别有吸引力。

研究设计与样本

  • 临床前研究:44Sc由PSI研究回旋加速器辐照富集44Ca靶标后经色谱分离生产。
  • 44Sc-PSMA-617在高温标准标记条件下制备,放化纯度>97%,比活度最高10 MBq/nmol。
  • 体外实验使用PSMA阳性PC-3 PIP和PSMA阴性PC-3 flu前列腺癌细胞,并与177Lu-和68Ga标记的PSMA-617及68Ga-PSMA-11比较。
  • 体内实验在PC-3 PIP/flu荷瘤小鼠中评估放射配体的分布与显像。

主要发现

  • 44Sc-PSMA-617在体外显示与177Lu-和68Ga标记的PSMA-617相似的特性。
  • 44Sc-PSMA-617特异性结合PSMA表达的PC-3 PIP肿瘤细胞,未观察到对PC-3 flu细胞的无特异性结合。
  • 44Sc-PSMA-617肿瘤摄取高、肾脏排泄快,整体组织分布最接近177Lu-PSMA-617。
  • 68Ga标记的配体尤其是68Ga-PSMA-11显示不同的分布动力学。
  • 44Sc-PSMA-617注射后不久即可清晰显像PC-3 PIP肿瘤异种移植,肿瘤-本底对比随时间增加,未观察到PC-3 flu肿瘤的无特异性摄取。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The targeting of the prostate-specific membrane antigen (PSMA) is of particular interest for radiotheragnostic purposes of prostate cancer. Radiolabeled PSMA-617, a 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-functionalized PSMA ligand, revealed favorable kinetics with high tumor uptake, enabling its successful application for PET imaging (68Ga) and radionuclide therapy (177Lu) in the clinics. In this study, PSMA-617 was labeled with cyclotron-produced 44Sc (T 1/2 = 4.04 h) and investigated preclinically for its use as a diagnostic match to 177Lu-PSMA-617. RESULTS: 44Sc was produced at the research cyclotron at PSI by irradiation of enriched 44Ca targets, followed by chromatographic separation. 44Sc-PSMA-617 was prepared under standard labeling conditions at elevated temperature resulting in a radiochemical purity of >97% at a specific activity of up to 10 MBq/nmol. 44Sc-PSMA-617 was evaluated in vitro and compared to the 177Lu- and 68Ga-labeled match, as well as 68Ga-PSMA-11 using PSMA-positive PC-3 PIP and PSMA-negative PC-3 flu prostate cancer cells. In these experiments it revealed similar in vitro properties to that of 177Lu- and 68Ga-labeled PSMA-617. Moreover, 44Sc-PSMA-617 bound specifically to PSMA-expressing PC-3 PIP tumor cells, while unspecific binding to PC-3 flu cells was not observed. The radioligands were investigated with regard to their in vivo properties in PC-3 PIP/flu tumor-bearing mice. 44Sc-PSMA-617 showed high tumor uptake and a fast renal excretion. The overall tissue distribution of 44Sc-PSMA-617 resembled that of 177Lu-PSMA-617 most closely, while the 68Ga-labeled ligands, in particular 68Ga-PSMA-11, showed different distribution kinetics. 44Sc-PSMA-617 enabled distinct visualization of PC-3 PIP tumor xenografts shortly after injection, with increasing tumor-to-background contrast over time while unspecific uptake in the PC-3 flu tumors was not observed. CONCLUSIONS: The in vitro characteristics and in vivo kinetics of 44Sc-PSMA-617 were more similar to 177Lu-PSMA-617 than to 68Ga-PSMA-617 and 68Ga-PSMA-11. Due to the almost four-fold longer half-life of 44Sc as compared to 68Ga, a centralized production of 44Sc-PSMA-617 and transport to satellite PET centers would be feasible. These features make 44Sc-PSMA-617 particularly appealing for clinical application.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Umbricht CA, Benešová M, Schmid RM, et al. 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617. EJNMMI Res. 2017. PMID: 28102507. doi:10.1186/s13550-017-0257-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。